Table 2.
a: Comparison between autoantibody-positive AIIRD patients to AIIRD patients without autoantibody production following second vaccine dose. b: Comparison between autoantibody-positive AIIRD patients to AIIRD patients without autoantibody production following third vaccine dose.
| (a) | ||||
|---|---|---|---|---|
| Any Autoantibody Positivity | No Autoantibody Positivity | p-Value | ||
| Number of patients with serologic data | n = 453 | 4.0% (n = 18) | 96.0% (n = 435) | |
|
Age
(Mean ± SD) |
57.8 ± 14.5 | 58.0 ± 14.6 | 0.942 | |
| Sex | Female | 4.9% (n = 16) | 95.1% (n = 312) | 0.176 |
| Male | 1.6% (n = 2) | 98.4% (n = 123) | ||
| Diagnosis | RA | 3.6% (n = 6) | 96.4% (n = 161) | 0.308 |
| PsA | 4.0% (n = 4) | 96.0% (n = 97) | ||
| SLE | 9.3% (n = 5) | 90.7% (n = 51) | ||
| AS | 7.1% (n = 3) | 92.9% (n = 39) | ||
| Vasculitis | 0.0% (n = 0) | 100% (n = 45) | ||
| SSCL | 0.0% (n = 0) | 100% (n = 23) | ||
| Myositis | 0.0% (n = 0) | 100% (n = 17) | ||
| SS | 0.0% (n = 0) | 100% (n = 1) | ||
| IgG4-RD | 0.0% (n = 0) | 100% (n = 1) | ||
| Vaccine immune response (seroconversion) | Yes | 4.7% (n = 16 of 338) |
95.3% (n = 322 of 338) |
0.492 |
| DMARDs | cDMARDs | 4.7% (n = 8) | 95.3% (n = 162) | 0.536 |
| bDMARDs | 3.9% (n = 10) | 96.1% (n = 246) | 0.933 | |
| tsDMARDs | 5.9% (n = 2) | 94.1% (n = 32) | 0.637 | |
| (b) | ||||
| Any Autoantibody Positivity | No Autoantibody Positivity | p -Value | ||
| Number of patients with serologic data | n = 355 | 7.7% (n = 31) | 80.0% (n = 324) | |
|
Age
(Mean ± SD) |
60.2 ± 13.7 | 58.4 ± 14.6 | 0.506 | |
| Sex | Female | 9.6% (n = 25) | 90.4% (n = 236) | 0.347 |
| Male | 6.4% (n = 6) | 93.6% (n = 88) | ||
| Diagnosis | RA | 12.0% (n = 16) | 88.0% (n = 117) | 0.604 |
| PsA | 6.3% (n = 5) | 93.8% (n = 75) | ||
| SLE | 4.9% (n = 2) | 95.1% (n = 40) | ||
| AS | 6.9% (n = 2) | 93.1% (n = 27) | ||
| Vasculitis | 10.8% (n = 4) | 89.2% (n = 33) | ||
| SSCL | 0.0% (n = 0) | 100% (n = 17) | ||
| Myositis | 13.3% (n = 2) | 86.7% (n = 13) | ||
| SS | 0.0% (n = 0) | 100% (n = 1) | ||
| IgG4-RD | 0.0% (n = 0) | 100% (n = 1) | ||
| Vaccine immune response (seroconversion) | Yes | 9.3% (n = 26 of 279) |
90.7% (n = 253 of 279) |
>0.99 |
| DMARDs | cDMARDs | 11.5% (n = 15) | 88.5% (n = 116) | 0.165 |
| bDMARDs | 7.5% (n = 15) | 92.5% (n = 185) | 0.350 | |
| tsDMARDs | 0.0% (n = 0) | 100% (n = 27) | 0.150 | |
Abbreviations: AS = ankylosing spondylitis, DMARDs = disease-modifying anti-rheumatic drugs, IGG4-RD = immonoglobulin G4-related disease, SSCL: classification criteria for systemic sclerosis, n = number, PsA = psoriatic arthritis, RA = rheumatoid arthritis, SD = standard deviation, SLE = systemic lupus erythematosus, and SS = Sjogren’s syndrome.